Applied Biosystems and Agilent Technologies sign technology access agreement

26-Jan-2001

Agilent Technologies Inc. (NYSE: A), a leading provider of innovative technologies for communications and life sciences; and Applied Biosystems Group (NYSE: ABI), an Applera Corporation business, today announced they have signed a technology access agreement for Agilent to supply custom in situ synthesized oligonucleotide microarrays to Applied Biosystems for research use. No further details of the agreement were disclosed.

Agilent in the Life Sciences

Agilent Technologies is a leading provider of total solutions, including consulting services, informatics software and tools for gene expression analysis, a fast-growing field of study that allows researchers to identify key gene transcriptional regulatory events or pathways associated with diseases or biologies. Researchers can select from pre-fabricated cDNA arrays or do rapid, iterative, hypothesis-driven research using custom-designed microarrays developed by Agilent to be delivered within days. Agilent is also a leading manufacturer of high-quality bioanalyzers and microarray scanners. Agilent supports the collaborative research efforts by the National Human Genome Research Institute (NHGRI) and others to analyze genome-wide patterns of mRNA expression, and is actively driving open data standards for gene expression research in alliance with Rosetta Inpharmatics Inc.

About Applera Corporation

Applera Corporation, formerly PE Corporation, comprises two operating groups. The Applied Biosystems Group (NYSE: ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. The Celera Genomics Group (NYSE: CRA), headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning (800) 762-6923.

For Applied Biosystems: Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Applied Biosystems businesses include but are not limited to (1) rapidly changing technology and dependence on new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; (3) claims for patent infringement; (4) significant overseas operations; (5) future growth strategy; (6) earthquakes; and (7) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission.

https://www.chemeurope.com/en/news/1015/applied-biosystems-and-agilent-technologies-sign-technology-access-agreement.html